US and UK Announce Duty-Free Accord on Pharmaceuticals.
The United Kingdom and the United States have hammered out a landmark trade agreement that will maintain no import taxes on UK drug products going into the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to increase expenditure on drugs through the public health system. This commitment ensures that tariffs on these vital exports will be held at nothing for a timeframe of 36 months.
This development comes after earlier threats to significantly raise tariffs on branded pharmaceutical imports, with increases discussed as high as 100%.
"This deal between the UK bolsters the global environment for innovative medicines and introduces much-needed fairness to transatlantic medicine commerce," a statement noted.
Commercial Significance
Medicines represent one of the UK's biggest goods shipped to the America, which is easily the biggest buyer for leading British pharmaceutical firms.
Export figures show that in the 12 months to the end of last September, the UK sold pharmaceutical products worth £11.1bn to the US. This value made up a significant portion of all goods exports in that period.
"This guarantee secures work, stimulates funding and sets the stage for the UK to become a worldwide center for medical research," a minister commented.
Specific UK Commitments
The agreement entails several notable commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the price threshold at which it deems new therapies to be too expensive by a quarter.
- Increased NHS Spending: There is a target to raise overall public funding on medicines from 0.3% of GDP to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must return to the NHS to control costs will be capped at 15%. Previously, repayments were more than 20%.
Recent Tensions
The deal follows a ongoing dispute between the sector and the ministers over spending levels and approval rates.
These tensions were exacerbated by assertions that US customers were charged significantly more for the same drugs than consumers in the Britain and the EU.
Recently, several significant drug company projects in the UK have been delayed or abandoned, while substantial expansions have been announced toward projects in the United States.
One official acknowledged that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a share of its resources over the past decade.
